Close Menu

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will collaborate with the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center on methods for detecting and tracking blood-based protein biomarkers for various cancers.

The work will focus on applying the company's liquid chromatography-mass spectrometry equipment along with its mass spectrometry immunoassay technology to identify markers for breast and prostate cancer as well as tumor-associated blood vessel formation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics.